Consistent with this, our studies demonstrate that T-DXd, DV, and tucatinib inhibit prostate cancer cell growth despite the presence of ASPN and suggest anti-HER2 therapies could have clinical efficacy, even with ASPN in the TME. Here, ERBB2 is linked to prostate carcinoma.